Literature DB >> 23033944

Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan.

Rikizo Taira1, Masahiro Satake, Shun'ya Momose, Satoru Hino, Yoshiharu Suzuki, Hiroyuki Murokawa, Shigeharu Uchida, Kenji Tadokoro.   

Abstract

BACKGROUND: Nucleic acid amplification testing (NAT) for hepatitis B virus (HBV) during blood screening has helped to prevent transfusion-transmitted HBV infection (TT-HBV) in Japan. Nevertheless, 4 to 13 TT-HBV infections arise annually. STUDY DESIGN AND METHODS: The Japanese Red Cross (JRC) analyzed repository samples of donated blood for TT-HBV that was suspected through hemovigilance. Blood donations implicated in TT-HBV infections were categorized as either window period (WP) or occult HBV infection (OBI) related. In addition, we analyzed blood from 4742 donors with low antibody to hepatitis B core antigen (anti-HBc) and antibody to hepatitis B surface antigen (anti-HBs) titers using individual-donation NAT (ID-NAT) to investigate the relationship between anti-HBc titer and proportion of viremic donors.
RESULTS: Introduction of a more sensitive NAT method for screening minipools of 20 donations increased the OBI detection rate from 3.9 to 15.2 per million, while also the confirmed OBI transmission rate increased from 0.67 to 1.49 per million. By contrast the WP transmission rate decreased from 0.92 to 0.46 per million. Testing repository samples of donations missed by minipools of 20 donations NAT showed that 75 and 85% of TT-HBV that arose from WP and OBI donations, respectively, would have been interdicted by ID-NAT. The ID-NAT trial revealed that 1.94% of donations with low anti-HBc and anti-HBs titers were viremic and that anti-HBc titers and the frequency of viremia did not correlate.
CONCLUSIONS: The JRC has elected to achieve maximal safety by discarding all units with low anti-HBc and anti-HBs titers that account for 1.3% of the total donations.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033944     DOI: 10.1111/j.1537-2995.2012.03909.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  14 in total

1.  Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018.

Authors:  Claudio Velati; Luisa Romanò; Ilaria Pati; Giuseppe Marano; Vanessa Piccinini; Liviana Catalano; Simonetta Pupella; Stefania Vaglio; Eva Veropalumbo; Francesca Masiello; Giulio Pisani; Giuliano Grazzini; Alessandro Zanetti; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  HBV DNA Test Among Blood Donations May Require Two Amplification Targets.

Authors:  Chao Liu; Le Chang; Lunan Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2019-01-18       Impact factor: 0.900

Review 3.  Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.

Authors:  Venkatakrishna Shyamala
Journal:  Asian J Transfus Sci       Date:  2014-01

Review 4.  Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing.

Authors:  Antonella Esposito; Chiara Sabia; Carmela Iannone; Giovanni F Nicoletti; Linda Sommese; Claudio Napoli
Journal:  Transfus Med Hemother       Date:  2017-05-05       Impact factor: 3.747

5.  A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections.

Authors:  Marion Vermeulen; Harry van Drimmelen; Charl Coleman; Josephine Mitchel; Ravi Reddy; Nico Lelie
Journal:  Transfusion       Date:  2014-04-21       Impact factor: 3.157

6.  Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors.

Authors:  David Juhl; Johannes K-M Knobloch; Siegfried Görg; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2015-11-04       Impact factor: 3.747

7.  Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy.

Authors:  M N dos S Moresco; H de A Virgolino; M P E de Morais; I da Motta-Passos; M S Gomes-Gouvêa; L M S de Assis; K R de L Aguiar; S C F Lombardi; A Malheiro; N de P Cavalheiro; J E Levi; K L Torres
Journal:  Vox Sang       Date:  2014-02-21       Impact factor: 2.144

8.  Serum analysis method combining cellulose acetate membrane purification with surface-enhanced Raman spectroscopy for non-invasive HBV screening.

Authors:  Yunchao Xu; Yunyi Wang; Huijin Lin; Xiaokun Liu; Zuci Zheng; Tingyin Wang; Shangyuan Feng
Journal:  IET Nanobiotechnol       Date:  2020-02       Impact factor: 1.847

9.  Prevalence of HBV DNA among 20 million seronegative blood donations in China from 2010 to 2015.

Authors:  Chao Liu; Le Chang; Huimin Ji; Fei Guo; Kuo Zhang; Guigao Lin; Rui Zhang; Jinming Li; Lunan Wang
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

10.  Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus.

Authors:  Marion Vermeulen
Journal:  Rev Bras Hematol Hemoter       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.